Log in
ASX:OSL

OncoSil Medical Limited (OSL.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.12
MA: A$0.12▼
A$0.12
52-Week Range N/A
Volume2.17 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.52 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolASX:OSL
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.oncosil.com.au
Phone61 2 9223 3344
EmployeesN/A

Debt

Debt-to-Equity Ratio0.50
Current Ratio11.08
Quick Ratio11.03

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.76 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow10.91
Book ValueA$0.03 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive OSL News and Ratings via Email

Sign-up to receive the latest news and ratings for OSL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OncoSil Medical Limited (OSL.AX) (ASX:OSL) Frequently Asked Questions

Who are some of OncoSil Medical Limited (OSL.AX)'s key competitors?

Some companies that are related to OncoSil Medical Limited (OSL.AX) include (BUX) (BUX), BARD1 Life Sciences Limited (BD1.AX) (BD1), Charles River Laboratories International (CRL), Cryosite Limited (CTE.AX) (CTE), dorsaVi Ltd (DVL.AX) (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Technologies Limited (GTG.AX) (GTG), Imagin Medical (IME), Imagion Biosystems Limited (IBX.AX) (IBX), Integral Diagnostics (IDX), Lifespot Health Ltd (LSH.AX) (LSH), Medical Imaging (MEDD), Parallax Health Sciences (PRLX) and Profound Medical (PRN).
View all competitors.

What other stocks do shareholders of OncoSil Medical Limited (OSL.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSil Medical Limited (OSL.AX) investors own include Champion Iron Limited (CIA.AX) (CIA), Blackmores Limited (BKL.AX) (BKL), APA Group (APA.AX) (APA), WiseTech Global (WTC), Twitter (TWTR), Qube Holdings Limited (QUB.AX) (QUB), The Procter & Gamble (PG) and Charter Hall Education Trust (CQE).

Who are OncoSil Medical Limited (OSL.AX)'s key executives?

OncoSil Medical Limited (OSL.AX)'s management team includes the following people:
  • Mr. Daniel Kenny B.Sc., CEO, MD & Exec. Director
  • Mr. Karl David Pechmann, Chief Financial Officer
  • Mr. Michael Warrener, Global Sales & Marketing Director
  • Dr. David Charles James, Global Head of Manufacturing Operations
  • Mr. Charles Rowland, Pres of US Operations (Age 69)

What is OncoSil Medical Limited (OSL.AX)'s stock symbol?

OncoSil Medical Limited (OSL.AX) trades on the ASX under the ticker symbol "OSL."

How big of a company is OncoSil Medical Limited (OSL.AX)?

OncoSil Medical Limited (OSL.AX) has a market capitalization of $0.00 and generates $2.76 million in revenue each year.

What is OncoSil Medical Limited (OSL.AX)'s official website?

The official website for OncoSil Medical Limited (OSL.AX) is www.oncosil.com.au.

How can I contact OncoSil Medical Limited (OSL.AX)?

The company can be reached via phone at 61 2 9223 3344.

This page was last updated on 10/24/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.